Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated with chronic kidney disease,
Semaglutide is now approved for reducing the risk for worsening kidney disease and cardiovascular death in adults with chronic kidney disease.
Regulators have approved the drug as a treatment for weight loss, Type 2 diabetes and lowering the risk of heart attacks and strokes.
Approval was based on results from the Phase IIIb FLOW trial, which demonstrated a 24% relative risk reduction in kidney disease, kidney failure, and cardiovascular death in patients treated with Ozempic.
The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of
Novo Nordisk (NVO) announced that the Food and Drug Administration has approved Ozempic to reduce the risk of kidney disease worsening, kidney
Novo Nordisk’s Ozempic (semaglutide) has been approved by the US Food and Drug Administration (FDA) to reduce the risk of kidney disease worsening, kidney failure and cardiovascular disease (CVD) death in adults with type 2 diabetes (T2D) and chronic kidney disease (CKD).
Novo Nordisk (NVO) said its popular diabetes drug Ozempic, or semaglutide, has been approved for the treatment of patients with chronic kidney disease and diabetes. Read more here.
The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go public.
The FDA has approved popular antiobesity drug Ozempic to help protect patients with type 2 diabetes from kidney disease.
Novo Nordisk will begin a new late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10, according to a entry.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback